

Applications: W	<b>Reactivity:</b> H M R Mk	<b>Sensitivity:</b> Endogenous	<b>MW (kDa):</b> 22	<b>Source/Isotype:</b> Rabbit	<b>UniProt ID:</b> #P28074	Entrez-Gene Id: 5693
Product Usage Information		<b>Application</b> Western Blotting			Dilution 1:1000	
Storage		Supplied in 10 mM soo 20°C. Do not aliquot tl		ö), 150 mM NaCl, 100 μg/	ml BSA and 50% gly	ycerol. Store at –
Specificity/Sensitivity		PSMB5 Antibody recognizes endogenous levels of total PSMB5 protein. Based upon sequence alignment, this antibody is predicted to react with precursor and mature forms of PSMB5. This antibody does not cross-react with PSMB8.				
Source / Purification		Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human PSMB5 protein. Antibodies are purified by protein A and peptide affinity chromatography.				
Background		ubiquitinated substrat particle (CP) and the 1 consists of two stacke flanked on either side having multiple subur belonging to the AAA function to unfold the unfolded substrate to function in recruitmer Other modulators of p and activate it (1,2). The core particle perfoc trypsin-like, and caspa (β5/MB1/X/LMPX/Mac (β1/Y/LMPY/Macropain terminal nucleophile ( residue active site: The nucleophile (on its sid catalytic β-subunits ar proteasome biogenes responsive cells the co highly homologous in PSMB8 (β5i/LMP7/RIN chymotrypsin-like and is downregulated at th	te proteins. It consi 9S/PA700 regulator d heteroheptameri by two heterohept nits. The base, in pa (ATPases Associate substrate and ope the catalytic β-sub to of ubiquitinated s proteasome activity orms three types of ase-like activities, w ropain epsilon chai n delta chain) subu Ntn) hydrolase fam e N-terminal threor e chain) and the pri te synthesized with is by limited proteco postitutively express duced β-subunits: F (G10), respectively, I trypsin-like activiti po f the proteasome (6-8). PSMB5 is also	t proteolytic complex inv sts largely of two sub-co cy particle (RP) that can c c $\beta$ -rings ( $\beta_{1-7}$ ) that conta americ $\alpha$ -rings ( $\alpha_{1-7}$ ). The rt, is composed of a hete d with diverse cellular Ac n the gate formed by the units. The lid consists of substrates and modificat , such as PA28/11S REG, catalytic activities inside hich are provided by the n), PSMB7 ( $\beta_2/Z/Macrop$ nits, respectively. These ily and are characterized ine of each proteolytic si mary proton acceptor ( $\alpha$ N-terminal propeptides, lysis to expose the catal Sed PSMB6, PSMB7, and PSMB9 ( $\beta_{11}/LMP2/RING1$ to form the immunoprot es known to be favorabl FN- $\gamma$ and replaced by PS for more appropriate imp o one of the predominar oteasome (9).	mplexes, the 20S ca ap either end of the ain three catalytic β- e RP includes a base prohexameric ring of tivities) family. The e α-subunits, thus ei- ubiquitin receptors ion of ubiquitin cha can also bind to the e its chamber: chym constitutively expre- ain chain Z) and PSI catalytic subunits b I by an unusual, ess ubunit provides boi n the main chain N which are removed PSMB5 subunits ar 2), PSMB10 (β2i/ME easome that has hi e for antigen proces MB8 in order to ren munological proces	atalytic core e CP. The CP -subunits and are e and a lid, each of ATPase subunits ATPase subunits xposing the and DUBs that in topology (1,2). e end of the 20S CP otrypsin-like, essed PSMB5 MB6 elong to the N- sentially single- th the catalytic -terminus). The d at the final step of ues (3). In immune e replaced by three ECL-1/LMP10) and igher ssing (4,5). PSMB5 nodel the ssing of
Background Re	ferences	1. Finley, D. (2009) <i>Ani</i> 2. Lee, M.J. et al. (2011 3. Murata, S. et al. (200 4. Boes, B. et al. (1994 5. Cardozo, C. and Koł 6. Akiyama, K. et al. (19 7. Akiyama, K. et al. (19 8. Gaczynska, M. et al. 9. Oorlomans, B. et al.	) <i>Mol Cell Proteom</i> 09) <i>Nat Rev Mol Cel</i> ) <i>J Exp Med</i> 179, 90 nanski, R.A. (1998) <i>J</i> 994) <i>Science</i> 265, 1 994) <i>FEBS Lett</i> 343, (1996) <i>J Biol Chem</i>	<i>ics</i> 10, R110.003871. / <i>Biol</i> 10, 104-15. 1-9. <i>Biol Chem</i> 273, 16764-7 231-4. 85-8. 271, 17275-80.	Э.	

9. Oerlemans, R. et al. (2008) *Blood* 112, 2489-99.

Species Reactivity	Species reactivity is determined by testing in at least one approved application (e.g., western blot).				
Western Blot Buffer	IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v nonfat dry milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.				
Applications Key	W: Western Blotting				
Cross-Reactivity Key	H: Human M: Mouse R: Rat Mk: Monkey				
Trademarks and Patents	Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.				
	All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.				
Limited Uses	Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.				
	Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purpose, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.				